Table 4:
Relative Odds of Completion of Adjuvant Therapy: Univariable and Multivariable Logistic Regression Models, Odds Ratios (95% CI)
| Univariable | P value | Overall P value | Multivariable | P value | Overall P value | |
|---|---|---|---|---|---|---|
| SED (reference: Low SED) | 0.637 | 0.462 | ||||
| Moderate SED | 0.79 (0.45, 1.40) | 0.423 | 0.64 (0.32, 1.29) | 0.215 | ||
| High SED | 1.04 (0.55, 1.99) | 0.904 | 0.82 (0.37, 1.86) | 0.634 | ||
| Age | 0.94 (0.91, 0.97) | <0.001 | 0.93 (0.88, 0.97) | 0.002 | ||
| Male sex (reference: female) | 0.79 (0.48, 1.30) | 0.360 | 0.68 (0.37, 1.25) | 0.220 | ||
| Race (reference: White) | 0.146 | 0.088 | ||||
| Black | 1.89 (0.56, 8.59) | 0.343 | 1.03 (0.25, 5.38) | 0.968 | ||
| Other / unknown | 6.24 (1.19, 114.92) | 0.082 | 14.14 (1.92, 310.59) | 0.028 | ||
| Insurance (reference: private) | 0.112 | 0.982 | ||||
| Government with private supplement | 0.56 (0.30, 1.04) | 0.071 | 0.99 (0.42, 2.32) | 0.987 | ||
| Government | 0.52 (0.26, 1.00) | 0.052 | 0.93 (0.37, 2.34) | 0.882 | ||
| Distance from Moffitt (miles) | 1.00 (0.99, 1.00) | 0.189 | 1.00 (0.99, 1.00) | 0.091 | ||
| Charlson comorbidity index | 0.80 (0.67, 0.95) | 0.012 | 1.03 (0.76, 1.40) | 0.848 | ||
| Diabetes mellitus (reference: no) | 0.69 (0.41, 1.19) | 0.179 | 0.78 (0.38, 1.60) | 0.497 | ||
| BMI | 1.02 (0.98, 1.07) | 0.346 | 1.06 (0.99, 1.12) | 0.076 | ||
| Preoperative biliary stent (reference: none) | 1.64 (0.99, 2.70) | 0.051 | 1.84 (0.88, 3.86) | 0.104 | ||
| Neoadjuvant Therapy (reference: none) | 0.88 (0.53, 1.47) | 0.609 | 0.75 (0.35, 1.60) | 0.451 | ||
| ASA class 3 (reference: ASA 2) | 0.47 (0.28, 0.79) | 0.005 | 0.89 (0.44, 1.82) | 0.747 | ||
| Distal pancreatectomy +/− splenectomy (reference: Whipple/total pancreatectomy) | 0.78 (0.43, 1.42) | 0.405 | 0.52 (0.18, 1.45) | 0.213 | ||
| Venous reconstruction (reference: none) | 0.42 (0.20, 0.84) | 0.015 | 0.64 (0.25, 1.66) | 0.354 | ||
| Estimated blood loss | 1.00 (1.00, 1.00) | 0.015 | 1.00 (0.99, 1.00) | 0.103 | ||
| Operative time | 0.94 (0.85, 1.04) | 0.213 | 0.88 (0.75, 1.02) | 0.082 | ||
| Pathologic tumor stage (reference: CR/in situ) | 0.275 | 0.443 | ||||
| T1 | 1.70 (0.38, 7.98) | 0.485 | 0.79 (0.13, 4.81) | 0.792 | ||
| T2 | 0.60 (0.19, 1.67) | 0.354 | 0.51 (0.12, 1.88) | 0.324 | ||
| T3 | 0.64 (0.19, 1.82) | 0.423 | 0.36 (0.08, 1.42) | 0.154 | ||
| Pathologic nodal stage (reference: N0) | 0.574 | 0.191 | ||||
| N1 | 1.34 (0.78, 2.32) | 0.300 | 2.11 (0.95, 4.76) | 0.069 | ||
| N2 | 1.21 (0.61, 2.45) | 0.586 | 1.69 (0.63, 4.69) | 0.306 | ||
| R1 Margin status (reference: R0) | 0.84 (0.39, 1.92) | 0.673 | 0.36 (0.13, 1.03) | 0.056 | ||
| Lymphovascular invasion (reference: none) | 0.94 (0.55, 1.60) | 0.826 | 0.48 (0.18, 1.21) | 0.126 | ||
| Perineural invasion (reference: none) | 1.24 (0.65, 2.33) | 0.505 | 2.20 (0.87, 5.64) | 0.096 | ||
| Clavien grade 3/4 complication (reference: none) | 0.49 (0.25, 0.97) | 0.038 | 0.33 (0.14, 0.77) | 0.011 |